July 28, 2014 6:26 AM ET

Pharmaceuticals

Company Overview of Aurobindo Pharma USA Inc.

Company Overview

Aurobindo Pharma USA Inc. manufactures generic pharmaceutical drugs. The company was incorporated in 2004 and is based in Dayton, New Jersey. Aurobindo Pharma USA Inc. operates as a subsidiary of Aurobindo Pharma Ltd.

6, Wheeling Road

Dayton, NJ 08810

United States

Founded in 2004

Phone:

609-716-1190

Fax:

609-716-8209

Key Executives for Aurobindo Pharma USA Inc.

Chief Executive Officer
Executive Chairman
Age: 56
Compensation as of Fiscal Year 2014.

Aurobindo Pharma USA Inc. Key Developments

Bristol-Myers Drags Aurobindo and Aurobindo Pharma USA Inc. to US Court

Bristol-Myers Squibb has dragged Aurobindo and its Aurobindo Pharma USA Inc. to the US District Court of New Jersey for alleged patent infringement of its anti-HIV drug 'Reyataz'. In its plea, BMS said legal action has been initiated against Aurobindo for infringement of patent no. 6,087,383 and asked the local American court to with hold approval to manufacture and market a generic version of BMS's Reyataz before the expiration of its patent on December 21, 2018. Bristol-Myers Squibb legal action follows an Abbreviated New Drug Application (ANDA) No 204806 filed by Aurobindo Pharma Ltd. with the US Food and Drug Administration (USFDA) for approval to manufacture and market a generic version of BMS's Reyataz drug product. BMS had clocked sales of $394 million from Reyataz in its fourth quarter ended December 31, 2014. Seeking relief from the US court, BMS stated that damages or other monetary relief must be granted to the company if Aurobindo engages in the commercial manufacture, use, sale of its generic product prior to expiration of the '383 patent. BMS further added that it will be irreparably harmed if Aurobindo's infringement is not enjoined by the court.

Aurobindo Pharma USA Inc. Announces Board Changes

Aurobindo Pharma Ltd. has announced that the board of directors of the company at its meeting held on August 25, 2012, have approved the proposal of appointment of Mr. P. V. Ramprasad Reddy as Executive Chairman of Aurobindo Pharma USA Inc., the wholly owned subsidiary of the company with effect from December 01, 2012. The said proposal is subject to further approval of the shareholders of the company. Accordingly, an Extra Ordinary General Meeting of the company is being convened on September 27, 2012. Consequent to his proposed appointment in the company's US subsidiary, the Board has also approved Mr. Ramprasad Reddy relinquishing the executive responsibilities as Wholetime Director of the company and his continuation as a Non-Executive Director of the company not liable to retire by rotation with effect from December 01, 2012.

Similar Private Companies By Industry

Company Name Region
Abbott Laboratories Residential Development Fund, Inc. United States
Makefield Therapeutics Inc. United States
Blueprint Medicines Corp. United States
FemmePharma Global Healthcare, Inc. United States
Eurand, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aurobindo Pharma USA Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.